Clinical Aspects of Sentinel Lymph Node Biopsy in Gastric Cancer

Dezso Toth*

Department of General Surgery, University of Debrecen, Kenezy Gyula University Hospital, Hungary

Received: May 19, 2018; Published: May 29, 2018

*Corresponding author: Dezso Toth, Department of General Surgery, University of Debrecen, Kenezy Gyula University Hospital, 2-26 Bartok Street, Debrecen 4031, Hungary

Abstract

Forty percent of patients with gastric cancer are node negative, so they have an unnecessarily extended lymph node dissection with a higher rate of morbidity and mortality. Successful sentinel lymph node (SLN) mapping may help to reduce the number of extended lymphadenectomy. Sentinel lymph node biopsy (SNB) is indicated in patients with T1 or T2 tumors; primary lesions < than 4 cm in diameter; and clinical N0 gastric cancer. The injection method and selection of tracers for SLN mapping in gastric cancer remain controversial. However, the use of dual tracer and in cases with non-palpable lesions, the submucosal marking method is recommended. The identification rate and sensitivity are the highest in time performing SNB biopsy after dye injection ≥15 min, the number of SLNs ≥5 and application of the basin dissection. The cardinal problem in the SNB concept is the intraoperative false negative rate, the combination of hematoxylin-eosin and immunohistochemical staining has the highest sensitivity of intraoperative pathologic detection by frozen tissue sections.

The application of SNB has a beneficial side effect, as it significantly increased the number of harvested LN and the ratio of the number of the harvested LN per time, although an extensive surgical experience is necessary for application of SNB concept. If the SLN contains tumor deposit(s), extended dissection is warranted, but if findings are negative, the patient could be spared additional complications associated with extended dissection. Finally, the SNB could be suitable for tumors following endoscopic resection and could represent a new era of sentinel node navigation surgery in early gastric cancer. However, the clinical application of SLN biopsy should be limited to the patients of cT1N0M0 gastric cancer within the confines of prospective randomized trial.

Keywords: Gastric Cancer; Surgery; Lymphadenectomy; Sentinel Node Biopsy

Introduction

The modern, optimal treatment of patients with different neoplasms can be achieved, in most cases, with the stage adapted, combined modality therapy according to international protocols. In case of solid tumors the presence and exact number, or the absence of lymph node (LN) metastases are among the most important prognostic factors as in gastric cancer, where the presence of lymph node metastases is the most important predictive factor of survival following curative resection [1,2]. Moreover, a lot of study proved that LN metastasis is an independent risk factor for local recurrence as well as the time interval between radical gastrectomy and hepatic metastasis in patients after R0 resection [3,4]. Almost three hundred thousand patients with gastric adenocarcinoma do not have lymph node metastasis in the one million new cases each year [5,6].

So, the one-third of patients with gastric adenocarcinoma has an unnecessarily extended lymph node dissection with a higher rate of morbidity and mortality. Preoperative imaging techniques provide a much more accurate determination of the T and M stage than that of the N stage. These preoperative diagnostic tools have a low sensitivity and specificity defining the patient subpopulation which would and which would not benefit from an extended lymph node dissection. For pathologic lymph node involvement the sensitivity, specificity and accuracy of spiral computer tomography is 73.1, 50.0 and 84.2%, respectively [7] and endoscopic ultrasonography has an accuracy of 68.6%, with a sensitivity and specificity of 66.7% and 73.7 %, respectively [8]. The real problem of these imaging procedures is that exclusion of endoscopic ultrasonography, only the size of the lymph nodes is taken into account.

In association with T stage, lymph node involvement can be found in 15% of patients with carcinoma confined to the mucosa, whereas lymph node metastases were detected in 23.4%, 48.2%, and 69.8% of patients with carcinoma invading the submucosa, muscular is propria and serous layer, respectively [9]. Gertler showed that not only infiltration of the submucosa but also lymphatic vessel invasion, multifocal tumor growth, younger patient age and poor tumor differentiation were associated with nodal
The correct status of lymph node metastases can be obtained only by histology following an optimally extended node dissection. The removal of further lymph nodes on the other hand, increases operative time, the rate of complications, and if negative may be considered unnecessary. The three earliest studies found a higher morbidity and mortality rate following extended lymph node dissection of patients with gastric cancer when compared to those undergoing D1 dissection only [14-16]. These higher rates were related mostly to splenectomy and pancreatectomy. Moreover, extended LN dissection did not have any effect on oncological outcomes. The relapse risk and survival were similar in these studies. Only the revision of the Dutch trial showed better survival in advanced disease in the D2 group, after 11-year follow-up [17]. The 15-year follow-up results revealed that cancer-related death rates were lower (37% versus 48%) with a lower rate of local recurrence in the D2 lymphadenectomy group (Table 1) [18].

Table 1: Sensitivity and specificity of SLN mapping procedure in correlation to the marking method (submucosal versus subserosal) [33].

<table>
<thead>
<tr>
<th>Submucosal (n=20)</th>
<th>Subserosal (n=37)</th>
<th>Result (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean number of SLN</td>
<td>4.3</td>
<td>5.4</td>
</tr>
<tr>
<td>Detection rate (%)</td>
<td>100%</td>
<td>97.3%</td>
</tr>
<tr>
<td>False negative rate (%)</td>
<td>0%</td>
<td>5.9%</td>
</tr>
<tr>
<td>Sensitivity (%)</td>
<td>100%</td>
<td>94.1%</td>
</tr>
<tr>
<td>Specificity (%)</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Criterion of equivalence: 95% of confidence interval (CI) should be fully within the range 0.8-1.25

The two latest randomized trials from the 21st century did not present significant differences in postoperative morbidity between the D1 and D2 group [19,20]. The morbidity rate was higher with D2 lymphadenectomy in the Taiwanese trial (which compared D1 to D3 dissection; however their D3 lymphadenectomy is similar to the current definition of D2 dissection). The Italian study did not show this difference and proved that D2 dissection could be performed safely without splenectomy and distal pancreatectomy, with comparable mortality and morbidity to those with D1 dissection in specialized centers [20,21]. These rates are comparable to the Japanese Clinical Oncology Group (JCOG) 9501 trial and the nationwide Japanese registry where the mortality was less than 2% after D2 dissection [22,23]. Neither did the latter study find any survival benefit from the extended lymphadenectomy [24]. These facts prove that the adequate extent of lymphadenectomy is controversial, even now. Successful sentinel lymph node (SLN) mapping may help to define those patients who would and those who would not benefit from an extended lymph node dissection in association with gastrectomy.

Technical Aspects of Sentinel Lymph Node Biopsy

Sentinel Lymph Node Detection Techniques

The first potentially affected lymph node, the sentinel lymph node, reliably reflects the status of the nodes in the second and third line, which is supported by data of numerous publications. The concept of sentinel lymph node biopsy (SNB) can determine the existence of LN metastases intraoperatively. This is a multistep technique consisted of six essential elements: indication, the selection of a tracer, a proper tracer injection method, the objective detection of SLNs, a reliable biopsy technique, and the precise detection of nodal metastasis [25].

Endoscopic and minor surgical gastric resections with D1 or modified D1 lymphadenectomies increased in EGC significantly. These minor procedures have been proved to have improved postoperative quality of life, while maintaining 5-year survival rates >95% [26]. In general, SLN mapping and biopsy is indicated in patients with T1 or T2 tumors; primary lesions <4 cm in diameter; and clinical NO gastric cancer [27]. The injection method and selection of tracers for SLN mapping in gastric cancer remain controversial. Studies from Japan and from Western Europe have demonstrated a high detection rate (95%) and a sensitivity of 90-95 percent [28-32]. Some authors use dye alone (patent blue, indocyanine green (ICG), isosulfan blue [31,33-35], while others 99m Tc colloid [28], and uses the combination of these tracers [36].

As reported by a meta-analysis, radioactive isotope alone got a pooled identification rate and sensitivity of 92.1 and 76.4% while dye alone was 92.1 and 72.7% [37]. The latest systematic review concluded that the use of dual tracer in SLN mapping got the highest identification rate and sensitivity (97.0 and 89.0%) [38]. There are some experimental results with carbon nanoparticles with promising results [39] and with the novel ICG fluorescence systems such as the D-light P system, the technique can be used in the room light and the laparoscopic surgery [38].

Keeping the well-known differences between Asian and European gastric cancer phenotypes in mind [40-42], Toth et al. have evaluated, for the first time, the SLN mapping using the blue dye only method in Hungary. After laparotomy, the lesser sac was opened (if it was needed) and 4 X 0.5 mL blue dye (Bleu Patente V Sodique Guerbet 2.5%, F-95943 Roissy CdG, Cedex, France) was injected in four quadrants around the tumor. Lymphatic drainage was observed for up to 15 minutes following injection. Blue stained lymph nodes were marked as sentinel lymph nodes and D2 lymph node dissection was performed after gastric resection or total gas-
In this investigation only the negative sentinel nodes were examined for micro metastasis, because of the widely recognized concept that lymphatic micro metastasis spread first to sentinel nodes in gastric cancer [43].

According to the marking techniques, earlier Yaguchi and Lee have compared the suberosal to the submucosal labeling method without any significant difference and they suggest the endoscopic injection of a tracer in cases of non-palpable tumors and/or laparoscopic procedures [44,45]. In the Hungarian study the submucosal and suberosal marking method (Figures 1 & 2) was proven equivalent in detection rate, sensitivity and specificity based on 95% confidence interval (CI) of ratio of indicators (Table 1) [33]. It is eminent that body-mass index (BMI) affects the sentinel lymph node detection rate [46]. The latter mentioned study proved that the identification of sentinel lymph nodes in obese patients can be difficult owing to the feathering of blue dye in the fatty tissue. This was concluded as the only patient in whom marking did not occur had a BMI significantly higher than average (26.8 versus 22.8) [33]. To avoid quick dispersal to multiple lymph nodes Kong applied ICG/poly-γ-glutamic acid (PGA) complex, which remained longer than diluted ICG in animal model [47].

The application of SNB has a beneficial side effect, as it significantly increased the number of harvested LN and the ratio of the number of the harvested LN per time [60]. During the Hungarian investigation any side-effect or complication with the blue dye method was not realized [33].

![Figure 1: Sentinel lymph node mapping following submucosal marking by an endoscopist.](Image 89x186 to 240x309)

![Figure 2: Suberosal labelling by a surgeon.](Image 100x353 to 229x475)

Multistep level sections, immunohistochemistry [52,53], reverse transcription polymerase chain reaction (RT-PCR) [54-57], and the one-step nucleic acid amplification assay (OSNA) [55], have all been developed to reduce the false-negative rates and provide reliable diagnostic tools for micro metastases in SLN. This latter technique (OSNA) is possible to reduce the detection time to ~30 min [58] and this test has similar results to postoperative 2-mm-interval histological examination for the intraoperative diagnosis of LN metastasis [59]. Shimizu et al. [57] developed a more sensitive real-time PCR method by using cytokeratin 19 mRNA, cytokeratin 20 mRNA, and carcinoembryonic antigen (CEA) mRNA. They have reported that approximately 30% of patients with pathologically negative LNs were positive for RT-PCR.

Advantages and Complications of Sentinel Lymph Node Biopsy

The application of SNB has a beneficial side effect, as it significantly increased the number of harvested LN and the ratio of the number of the harvested LN per time [60]. During the Hungarian investigation any side-effect or complication with the blue dye method was not realized [33].
Management of Positive And Negative Sentinel Lymph Node Biopsy

If the SLN contains tumor deposit(s), extended dissection is warranted, but if findings are negative, the patient could be spared additional complications associated with extended dissection. Based on the results of the largest prospective multi-center trial from Japan with an identification rate of 97.5% and an accuracy of 99% [51], a phase III multi-center trial for individualized surgery for EGC based on SLN mapping has been commenced in the Eastern Asian countries. The long-term results of these studies will be available between 2018 and 2020.

Conclusion

Dutch and British prospective randomized trials found a higher morbidity and mortality rate following extended lymph node dissection of patients with gastric cancer when compared to those undergoing D1 dissection only [15,16]. The preoperative diagnostic tools have a low sensitivity and specificity defining the patient subpopulation which would and which would not benefit from an extended lymph node dissection. Recent studies and the latest meta-analysis of SLN mapping have shown a high detection rate [93.7%] and an accuracy of 92% [37] and suggest that the SNB concept could be suitable for tumors following endoscopic resection [61] and could represent a new era of sentinel node navigation surgery in early gastric cancer [62,63]. Various mapping techniques have been described in the literature. The injection method and selection of tracers for SLN mapping remain controversial. However, the equivalence between the submucosal marking and the subserosal injection was proved. In cases of non-palpable tumors, the endoscopic submucosal injection is the preferred technique. Finally, the clinical application of SLN biopsy should be limited to the patients of cT1N0M0 gastric cancer within the confines of prospective randomized trials.

References


